Intelligent Bio Solutions (NASDAQ:INBS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Intelligent Bio Solutions (NASDAQ:INBS) from a hold rating to a sell rating in a research note released on Sunday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Intelligent Bio Solutions currently has a consensus rating of “Sell”.

Intelligent Bio Solutions Price Performance

INBS stock opened at $1.06 on Friday. The company’s 50 day simple moving average is $1.37 and its 200-day simple moving average is $1.48. The firm has a market capitalization of $9.62 million, a PE ratio of -0.52 and a beta of 4.49. Intelligent Bio Solutions has a 12 month low of $1.01 and a 12 month high of $2.75.

Intelligent Bio Solutions (NASDAQ:INBS) last released its quarterly earnings results on Friday, August 15th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.25). The business had revenue of $0.84 million during the quarter, compared to analyst estimates of $4.30 million. Intelligent Bio Solutions had a negative net margin of 346.22% and a negative return on equity of 231.13%. As a group, sell-side analysts anticipate that Intelligent Bio Solutions will post -1.25 earnings per share for the current year.

Hedge Funds Weigh In On Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Altium Capital Management LLC acquired a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 149,252 shares of the company’s stock, valued at approximately $215,000. Intelligent Bio Solutions accounts for about 0.5% of Altium Capital Management LLC’s holdings, making the stock its 17th largest holding. Altium Capital Management LLC owned 2.19% of Intelligent Bio Solutions as of its most recent SEC filing. Institutional investors own 32.97% of the company’s stock.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.